For two years, millions of GLP-1 patients relied on compounded semaglutide as a cheaper, more accessible alternative to brand-name Ozempic and Wegovy. That window has closed. The FDA resolved the semaglutide shortage in early 2025, triggering enforcement actions that effectively ended large-scale compounded semaglutide access. Here's what actually changed — and what patients should do next.
In February 2025, the FDA declared the semaglutide injection shortage officially resolved. This single determination had cascading legal effects: under Section 503A and 503B of the Food, Drug, and Cosmetic Act, compounding pharmacies are only permitted to compound drugs that are on the FDA's official shortage list. Once semaglutide was removed from that list, the legal basis for most compounded semaglutide evaporated.
The FDA gave enforcement grace periods — 60 days for 503A state-licensed pharmacies and 90 days for 503B outsourcing facilities — but those deadlines passed by May 2025. Compounders who continued dispensing semaglutide after those dates faced FDA warning letters and potential legal action.
If your pharmacy is still dispensing compounded semaglutide in 2026, they may be operating outside the law — or exploiting limited exemptions. Compounded products from non-compliant facilities may not meet the same purity and sterility standards as FDA-approved drugs. Consider transitioning to an FDA-approved product.
Not all compounded semaglutide became illegal overnight. Two narrow exemptions still exist:
A 503A pharmacy may compound semaglutide for a specific patient with a documented allergy to an inactive ingredient in the commercial product (e.g., a preservative in Ozempic or Wegovy), if that compounded version addresses the allergy and is prescribed by a licensed practitioner.
Compounds that are meaningfully different from approved products — such as different delivery mechanisms or concentrations not available commercially — may be permissible, but this is a narrow exception that the FDA is actively scrutinizing.
No — and it never did. Insurance will not cover compounded medications when an FDA-approved equivalent is available on the market. Now that Ozempic and Wegovy are commercially available, there is no circumstance under which a standard insurance plan will reimburse compounded semaglutide.